European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
Breast Cancer Res Treat. 2010 Nov;124(1):141-51. doi: 10.1007/s10549-010-1115-5. Epub 2010 Aug 15.
Intraoperative radiotherapy with electrons (ELIOT) after conservative surgery for breast carcinoma was introduced at the IEO in 1999 as a research programme. The results on 1,822 patients treated from January 2000 to December 2008 are reported. Women with unicentric primary breast carcinoma of less than 2.5 cm in the largest diameter were assessed by imaging. All patients were treated with breast-conserving surgery (quadrantectomy). ELIOT was delivered by two mobile linear accelerators immediately after breast resection with a single dose of 21 Gy. Local side effects of ELIOT were mainly liponecrosis (4.2%) and fibrosis (1.8%). After a mean follow-up of 36.1 months, 42 women (2.3%) developed a local recurrence, 24 (1.3%) a new primary ipsilateral carcinomas and 26 (1.4%) distant metastases as first event. Forty-six women died (2.5%), 28 for breast carcinoma and 18 for other causes. Five- and ten-year survivals were, respectively, 97.4 and 89.7%. ELIOT appears a promising feature in early breast cancer treated with breast conserving surgery, reducing the exposure of normal tissues to radiations and shortening the radiation course from 6 weeks to one single session.
1999 年,欧洲肿瘤研究所(IEO)开始将乳腺癌保乳术后电子内放疗(ELIOT)作为一项研究计划。报告了 2000 年 1 月至 2008 年 12 月期间治疗的 1822 例患者的结果。通过影像学评估患有最大直径小于 2.5cm 的单中心原发性乳腺癌的女性。所有患者均接受保乳手术(象限切除术)治疗。ELIOT 由两台移动线性加速器在乳房切除术后立即进行,单次剂量为 21Gy。ELIOT 的局部副作用主要是脂肪坏死(4.2%)和纤维化(1.8%)。平均随访 36.1 个月后,42 名女性(2.3%)出现局部复发,24 名(1.3%)出现同侧新原发性乳腺癌,26 名(1.4%)出现远处转移作为首发事件。46 名女性死亡(2.5%),28 名死于乳腺癌,18 名死于其他原因。5 年和 10 年生存率分别为 97.4%和 89.7%。ELIOT 似乎是保乳手术后早期乳腺癌治疗的一个很有前途的特征,它可以减少正常组织对辐射的暴露,并将放疗疗程从 6 周缩短至单次治疗。